Roche CEO Says Company Is Watching U.S. Tax Plans Closely

The transcript covers Roche's early 2017 performance, discussing sales growth and guidance. It addresses the impact of biosimilars on the market, particularly for rituximab, and outlines Roche's strategy to innovate and rejuvenate its portfolio. The discussion highlights new developments in multiple sclerosis and oncology, including the launch of Tecentriq and advancements in cancer immunotherapy. The potential impact of US tax changes on Roche's operations is also explored, emphasizing the importance of innovation and competitiveness in the US market.

What were the sales growth figures mentioned for the start of the year?

How does the company plan to adapt its guidance based on market performance?

What impact do biosimilars for rituximab have on the market according to the discussion?

What is the significance of the new medicine called Cassava?

What are the major opportunities identified for the future in the multiple sclerosis space?

What are the new therapeutic areas Roche is extending into?

How does the CEO view the impact of potential tax changes in the United States?